Comparative Pharmacology
Head-to-head clinical analysis: ECONAZOLE NITRATE versus FULVICIN U F.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ECONAZOLE NITRATE versus FULVICIN U F.
ECONAZOLE NITRATE vs FULVICIN-U/F
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Econazole nitrate, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase (CYP51), blocking ergosterol synthesis, disrupting fungal cell membrane integrity and function.
Inhibition of fungal cell mitosis by binding to microtubules, disrupting spindle formation and nuclear division.
Topical: Apply a thin layer to affected area twice daily (morning and evening). Vaginal: One applicatorful (150 mg) intravaginally at bedtime for 3 days. Rectal candidiasis: One 150 mg suppository rectally at bedtime for 3 days.
125 mg orally once daily with a high-fat meal for 7 days, then 125 mg every other day for 7 days (total 13 doses).
None Documented
None Documented
Terminal elimination half-life approximately 8-10 hours; clinical relevance: supports twice-daily topical dosing for sustained antifungal effect.
Terminal half-life approximately 9.5 hours; may be prolonged in liver disease.
Primarily hepatic metabolism; <1% unchanged in urine; 30-45% in feces as metabolites; minimal biliary excretion.
Primarily hepatic metabolism; <1% excreted unchanged in urine; metabolites excreted in bile and feces.
Category A/B
Category C
Antifungal
Antifungal